ClinicalTrials.gg
TerminatedNCT00141310Updated Feb 1, 2021

Sildenafil Citrate for the Treatment of Established Pre-Eclampsia

A Phase 2 interventional study of Sildenafil citrate in Pre-eclampsia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 10 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study prematurely discont'd 20-Apr-2006 after interim analysis suggested sample size could be reduced without losing power. No safety concerns led to decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Pre-Eclampsia with a site in United Kingdom — 7 open to participants now, 9 under way, 1 of them phase 3. Pre-Eclampsia · United Kingdom.

Enrollment
10th of 12
76 · median 202
Started
2004
the only one that year
Phase 2
Only one
of the 29
Registered
1st of 29
by date

Among the 29 studies in Pre-Eclampsia with a site in United Kingdom, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2004, is the only one in phase 2, and was the 1st registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 245 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

7 of the 29 studies in Pre-Eclampsia with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 162 Pre-Eclampsia studies recruiting now, 81 (50%) set no upper age limit and 80 (49%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Pre-Eclampsia with a site in United Kingdom, or all of them as a file.
02

Study summary

To determine the efficacy and safety of sildenafil citrate in the treatment of established pre-eclampsia

03

Conditions studied

  • Pre-eclampsia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with pre-eclampsia defined as new hypertension with a diastolic BP of > or = 90 mmHg on two occasions separated by at least 4 hrs arising after 20 weeks of pregnancy, associated with >500 mg/24 hr proteinuria. Subjects with pre-existing hypertension (on treatment) need only fulfill proteinuria requirement.
  • Gestational age 24-34 w
  • Singleton pregnancy

Exclusion criteria

Exclusion Criteria:

  • Where urgent delivery is indicated
  • Where the fetus is suspected to have a structural or chromosomal abnormality
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
76 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Primary endpoint is the time from randomization to delivery.

Secondary outcomes

  1. Individualised birth-weight ratio at delivery, Placental weight, Umbilical artery pulsatility index, Other indices of PET (incl. uric acid and maternal BP), Safety and toleration, Population PK, Fetal exposure (PK)

07

Study locations

10 sites
  • Pfizer Investigational Site
    Pembury, Kent TN2 4QJ, United Kingdom
  • Pfizer Investigational Site
    Royal Tunbridge Wells, Kent TN1 1JU, United Kingdom
  • Pfizer Investigational Site
    Ashton under Lyne, Lancs 0L6 9RW, United Kingdom
  • Pfizer Investigational Site
    Bolton, BL4 0JR, United Kingdom
  • Pfizer Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Pfizer Investigational Site
    Fife, KY2 5RA, United Kingdom
  • Pfizer Investigational Site
    London, SE1 7EH, United Kingdom
  • Pfizer Investigational Site
    London, SW10 9NH, United Kingdom
  • Pfizer Investigational Site
    Manchester, M14 0JH, United Kingdom
  • Pfizer Investigational Site
    Manchester, M6 8HD, United Kingdom
08

References and documents

Publications

  • Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy. 2009 Aug;28(4):369-82. doi: 10.3109/10641950802601278. PubMed 19843000 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004 and a completion of Apr 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Sep 2004
CompletionActual
Apr 2006
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00141310
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Sep 2004
Completion
Apr 2006
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion